The Cocktail Report (sounds really smart around your friends):
Researchers at UC Davis and UC San Francisco identified a brain-derived hormone called CCN3 (also known as the Maternal Brain Hormone) that directly stimulates skeletal stem cells to build new bone, rather than simply slowing bone loss like most existing drugs.
In mouse models, CCN3 delivered via a hydrogel patch accelerated fracture healing and dramatically increased bone density and strength.
The same hormone also shows promise for cartilage regeneration, meaning it could eventually treat both osteoporosis (a disease that weakens bones) and osteoarthritis (a disease that destroys joint cartilage) with a single approach.
The study, published in Nature, revealed that CCN3 is the mechanism the brain uses to protect bones during breastfeeding, when calcium demand is at its highest and skeletal integrity is most at risk.
The researchers have co-founded a company to accelerate clinical translation, and NIH grant applications are already in motion to advance human trials.
Two of the most common threats to mobility and independence as we age just got a new and unexpected adversary: a hormone produced by the brain. Researchers at UC Davis and UC San Francisco have published a landmark study in Nature identifying a molecule called CCN3 that could reshape how medicine treats both osteoporosis and osteoarthritis.
This matters to you because these are not rare diseases. Osteoporosis (a condition that progressively weakens bones and raises fracture risk) and osteoarthritis (the degenerative breakdown of joint cartilage) together affect roughly 33 million adults in the United States, and both are closely tied to the aging process.
The discovery began with a question about breastfeeding: during lactation, the body's calcium demands spike sharply, which can significantly weaken bone. The UC Davis and UCSF team traced the brain's protective response to CCN3, a hormone released by the hypothalamus (the brain region that regulates many of the body's core biological functions).
What they found went well beyond breastfeeding. CCN3 directly activates skeletal stem cells (specialized cells in bone marrow capable of generating new bone and cartilage tissue) to form fresh bone, and in mouse models, treated animals produced nearly three times the bone mass of untreated controls.
Applied via a hydrogel patch to fracture sites in elderly mice, the hormone accelerated healing and improved outcomes significantly.
That is a meaningful distinction from most current osteoporosis drugs, which work primarily by slowing the breakdown of bone. CCN3 appears to rebuild it, placing it in a rare and valuable category of anabolic (tissue-building) therapies.
The cartilage connection adds another dimension: researcher Thomas Ambrosi found that combining CCN3 signaling with controlled microinjuries can direct skeletal stem cells to form stable cartilage. This approach could prevent osteoarthritis in younger athletes with joint damage or help regenerate lost cartilage in middle-aged and older patients.
The research team has co-founded a company to move toward clinical application, and the technology is exclusively licensed through the University of California. NIH and National Institute on Aging grants are in progress to advance the next stage of studies.
Why Should You Care?
Bone fractures in older adults are not minor inconveniences. A hip fracture after 70 carries a mortality rate that rivals many cancers, and loss of mobility from joint disease is one of the leading causes of lost independence in later life.
A hormone that can rebuild bone and regenerate cartilage from a single biological pathway is the kind of discovery that the longevity field has been searching for. For anyone invested in staying strong, mobile, and self-sufficient well into their later decades, this one is worth watching closely.
Sources:
UC Davis Office of Research: Scientists Identify Hormones That May Offer Hope for Osteoporosis and Osteoarthritis Patients, February 24, 2026
Primary study published in Nature, UC Davis Health, and UC San Francisco research team led by Holly Ingraham, Nancy E. Lane, and Thomas H. Ambrosi
